Navigation Links
Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
Date:5/6/2008

ive of a new class of improved variants of factor VIIa discovered using Catalyst's proprietary protease engineering platform and know-how. Created within 12 months from program start up, CB 813 and related compounds demonstrate the power of our platform."

About Hemophilia

Hemophilia is a rare but serious bleeding disorder that results from a genetic or an acquired deficiency of a protein required for normal blood coagulation, such as factor VIII (hemophilia A) or factor IX (hemophilia B) in addition to factor VIIa for refractory hemophilia A and hemophilia B patients. Hemophilia patients suffer from potentially life-threatening spontaneous bleeding episodes and substantially prolonged bleeding times upon injury. In cases of severe hemophilia, spontaneous bleeding into muscles or joints is frequent and often results in permanent, disabling joint damage.

Hemophilia patients are initially treated by replacement therapy, receiving purified versions of the clotting factor in which they are deficient. However, a significant number of hemophilia A patients develop inhibitory antibodies against factor VIII and therefore become refractory to this treatment. These patients are then treated with factor VIIa, a protease enzyme that can both initiate blood clotting and, at high doses, "bypass" the factor VIII-dependent step in coagulation. Hemophilia B patients refractory to factor IX may also be treated with factor VIIa.

About Catalyst Biosciences

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases to target proteins underlying disease. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates, called Alterase(TM) therapeutics, that are applicable across a broad spectrum of disease categories. Initially, Catalyst is focusing its product development efforts on Alterase drug candidates for hemophilia, age-related macular dege
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
2. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
3. Neurocrine Biosciences Reports First Quarter 2008 Results
4. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
8. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
9. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Research and Markets( http://www.researchandmarkets.com/research/58tdl6/pharmaceutical ... Grade Sodium Chloride Market by Applications, by Region - ... their offering. The pharmaceutical grade sodium chloride ... between 2014 and 2019 in terms of volume, and ... 2019. The report on Pharmaceutical grade sodium ...
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... 6, 2015 Akcea Therapeutics, a wholly-owned ... ), announced today that the U.S. Food and ... volanesorsen (ISIS-APOCIII Rx ) for the treatment of ... a rare genetic disease characterized by extremely high ... Phase 2 study published in the NEJM in ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6
... Oct. 7 Cornerstone Pharmaceuticals, Inc., a privately-held pharmaceutical ... A. Weinberg, Ph.D., a founding member of the Whitehead ... at MIT, has joined the company,s Scientific Advisory Board. ... first human oncogene (the ras oncogene that ...
... MAARSSEN, The Netherlands, Oct. 7 CPhI Worldwide ... largest annual meeting - returns to Madrid on 12 - 15 ... contract services and P-MEC equipment and technology events ... banner by the new, biotech-focused BioPh . The new ...
Cached Medicine Technology:Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board 2Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board 3CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 2CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 3
(Date:7/6/2015)... , ... July 06, 2015 , ... University of ... national guidelines for thyroid cancer testing to reflect newly available tests that better incorporate ... use and how to interpret thyroid cancer tests is published in the July issue ...
(Date:7/6/2015)... ... ... a report titled “ Female Hair Loss Needs to be Talked About, Shed Stigma, Experts ... the U.S. will suffer from thinning hair or hair loss . For these 30 million ... beauty queen, who was interviewed for the report began losing her hair at age 11 due ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... Practice & Medical Spa industries, announces the return of its complimentary educational ... team of aesthetic medical business leaders creates success for their clients through targeted ...
(Date:7/6/2015)... Beach, Virginia (PRWEB) , ... July 06, 2015 ... ... States choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction ... country. For a particular demographic, however, fat reduction has become more than a ...
(Date:7/6/2015)... BC (PRWEB) , ... July 06, 2015 , ... Olive ... received the UBC 2014-2015 Post Graduate Teaching Award on behalf of the department of ... is a very exciting field to be practicing in. The technology is changing so ...
Breaking Medicine News(10 mins):Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2
... that children of mothers who smoke in their late pregnancies ... teens.// ,Dr Fran O'Callaghan of Griffith University's Psychological ... the University of Queens land had conducted their research on ... study, which is published in the latest edition of the ...
... Hopkins and the University of Michigan have developed a treatment ... ,The findings will be published in the July 18 ... The study has implications for treating people who may face ... nerves are wrenched from the spinal cord. The new treatment ...
... may have ruled out insufficient oxygen supply to the ... heart survives while in a hypothermic state.// ... of Physiology-Heart and Circulatory Physiology, researchers found no significant ... heart between rats exposed to one hour of severe ...
... outbreak of the deadly H5N1-type bird flu in a north-western ... over 3.5 lakh poultry.// ,The outbreak occurred on ... Aksu city, and the H5N1 virus was found in the ... laboratory, the Ministry of Agriculture said., ,The H5N1 strain ...
... NHS Greater Glasgow and Clyde are providing dental service for ... on the 20th of July. It is mainly to cater ... and those living in temporary accommodation. The service consists of ... it was found that homeless people have high levels of ...
... to the Auckland University School of Population health lecturers ... increase in the number of patients// who were victims ... was published in the New Zealand Medical Journal mainly ... led to an unacceptable number of patients suffering adverse ...
Cached Medicine News:Health News:Children Of Mothers Who Smoked Late In Pregnancies Tend To Be Smokers 2Health News:Scientists Coax Nerve Fibers to Regrow After Spinal Cord Injury 2Health News:Scientists Coax Nerve Fibers to Regrow After Spinal Cord Injury 3Health News:Scientists Coax Nerve Fibers to Regrow After Spinal Cord Injury 4Health News:Heart Has Enough Oxygen to Survive Hypothermia; CPR Crucial 2Health News:Heart Has Enough Oxygen to Survive Hypothermia; CPR Crucial 3
... cleanser will not leave your hands dry, ... With persistent Antimicrobial action, CHG Skin Cleanser ... gram-negative and gram-positive bacteria, fungi, and yeasts. ... second hand wash. The solution does not ...
IV Prep Antiseptic Wipes are effective and easy to apply. They are ideal for preparation of the skin prior to a ventipuncture or injection....
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
... Triad Plus Skin Protectant Swabsticks prepare ... dressing or bandage. When dry, they leave ... This provides a clean surface and a ... affect the adhesion of a dressing or ...
Medicine Products: